Research & Development
Development of Diagnostics for the Detection of Autoantibodies
MBL has developed in vitro diagnostics for a number of autoimmune diseases, and provides many products to hospitals, healthcare facilities, and clinical laboratories. We hold more than 90% of the domestic market share in terms of diagnostics for autoimmune diseases. New pathological conditions and autoantibodies in autoimmune diseases are being discovered even today. We continue the development of new diagnostics for novel autoimmune diseases.
Recently, many new autoantibodies have been found in polymyositis and dermatomyositis; specifically autoantibodies against aminoacyl-tRNA synthetase (ARS) and a novel autoantibody called anti-CADM-140 (MDA5). Depending on the type of autoantibodies present in the serum of patients with polymyositis or dermatomyositis, the clinical symptoms are different, and consequently, therapeutic strategies are also different. Thus, in vitro diagnostics that can enable the identification of these new autoantibodies are currently in demand in clinical practice. We have completed a new kit for the detection of anti-ARS autoantibodies. This kit got approved by the Pharmaceuticals and Medical Devices Agency (PMDA), Japan, and released to market on January 2014. In addition, we have also started to develop a detection kit for anti-CADM-140 autoantibodies, and are aiming to develop in vitro diagnostics.